In summary, PET-based intratumor heterogeneity could serve as a powerful and non-invasive approach to predict MYCN amplification and survival outcome in newly diagnosed neuroblastoma, providing a potential approach to refine the risk stratification in children with high-risk diseases. The gene discussed is MYCN; the disease is neuroblastoma.